RT Journal Article
SR Electronic
T1 Genetic Risk of Reticular Pseudodrusen in Age-Related Macular Degeneration: <em>HTRA1</em>/lncRNA <em>BX842242.1</em> dominates, with no evidence for Complement Cascade involvement
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.26.24314339
DO 10.1101/2024.09.26.24314339
A1 Farashi, Samaneh
A1 Abbott, Carla J
A1 Ansell, Brendan RE
A1 Wu, Zhichao
A1 Altay, Lebriz
A1 Arnon, Ella
A1 Arnould, Louis
A1 Bagdasarova, Yelena
A1 Balaskas, Konstantinos
A1 Chen, Fred K
A1 Chew, Emily
A1 Chowers, Itay
A1 Clarke, Steven
A1 Cukras, Catherine
A1 Delcourt, Cécile
A1 Delyfer, Marie-Noëlle
A1 den Hollander, Anneke I.
A1 Fauser, Sascha
A1 Finger, Robert P.
A1 Gabrielle, Pierre-Henry
A1 Han, Jiru
A1 Hodgson, Lauren AB
A1 Hogg, Ruth
A1 Holz, Frank G
A1 Hoyng, Carel
A1 Kumar, Himeesh
A1 Lad, Eleonora M
A1 Lee, Aaron
A1 Luhmann, Ulrich FO
A1 Mauschitz, Matthias M
A1 McKnight, Amy J
A1 McLenachan, Samuel
A1 Mishra, Aniket
A1 Moghul, Ismail
A1 Orozco, Luz D
A1 Sampson, Danuta M
A1 Scott, Liam W
A1 Sitnilska, Vasilena
A1 Song, Scott
A1 Stockwell, Amy
A1 Swaroop, Anand
A1 Terheyden, Jan H
A1 Tiosano, Liran
A1 Tufail, Adnan
A1 Yaspan, Brian L
A1 ,
A1 ,
A1 Pébay, Alice
A1 Fletcher, Erica L
A1 Guymer, Robyn H
A1 Bahlo, Melanie
A1 
YR 2024
UL http://medrxiv.org/content/early/2024/09/28/2024.09.26.24314339.abstract
AB Age-related macular degeneration (AMD) is a multifactorial retinal disease with a large genetic risk contribution. Reticular pseudodrusen (RPD) is a sub-phenotype of AMD with a high risk of progression to late vision threatening AMD. In a genome-wide association study of 2,165 AMD+/RPD+ and 4,181 AMD+/RPD-compared to 7,660 control participants, both chromosomes 1 (CFH) and 10 (ARMS2/HTRA1) major AMD risk loci were reidentified. However association was only detected for the chromosome 10 locus when comparing AMD+/RPD+ to AMD+/RPD-cases. The chromosome 1 locus was notably absent. The chromosome 10 RPD risk region contains a long non-coding RNA (ENSG00000285955/BX842242.1) which colocalizes with genetic markers of retinal thickness. BX842242.1 has a strong retinal eQTL signal, pinpointing the parafoveal photoreceptor outer segment layer. Whole genome sequencing of phenotypically extreme RPD cases identified even stronger enrichment for the chromosome 10 risk genotype.Competing Interest StatementFINANCIAL COMPETING INTERESTS Funding Research support to the author or their institution (including salaries, equipment, supplies and other expenses) by organizations that may gain or lose financially through this publication. A specific role for the funder in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript, should be disclosed. Employment Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through this publication. Personal financial interests Stocks or shares in companies that may gain or lose financially through publication; consultation fees or other forms of remuneration (including reimbursement for attending symposia) from organizations that may gain or lose financially; patents or patent applications (awarded or pending) filed by the authors or their institutions whose value may be affected by publication. For patents and patent applications, disclosure of the following information is requested: patent applicant (whether author or institution), name of inventor(s), application number, status of application, specific aspect of manuscript covered in patent application SC - employee (Genentech Inc) AIdH - employee (AbbVie Inc) SFauser - is an employee of F. Hoffmann-La Roche Ltd. UFOL - is an employee of and has financial interest in F. Hoffmann-La Roche Ltd. LDO - employee (Genentech Inc) AStockwell - employee (Genentech Inc) JHT - grant funding (Norvartis, Bayer, Roche), received speaker fees (Novartis), consulting fees (Okko) BLY - employee (Genentech Inc) All other authors have no financial competing interests to disclose. These funders had no role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of this manuscript, with the exception of Genentech Inc (data collection and provision of summary statistics analysis of the Genentech cohort). NON-FINANCIAL COMPETING INTERESTS Non-financial competing interests can take different forms, including personal or professional relations with organizations and individuals. We would encourage authors and referees to declare any unpaid roles or relationships that might have a bearing on the publication process. Examples of non-financial competing interests include (but are not limited to): Unpaid membership in a government or non-governmental organization Unpaid membership in an advocacy or lobbying organization Unpaid advisory position in a commercial organization Writing or consulting for an educational company Acting as an expert witness All authors have no non-financial competing interests to disclose.Funding StatementThis work was supported by a National Health and Medical Research Council (NHMRC) of Australia Synergy grant to MB, BREA, RHG, ZW, ELF, and AP (GNT1181010). BREA is supported by an NHMRC Early Career Fellowship (GNT1157776), MB, RHG and ZW are supported by NHMRC Investigator Grants (GNT1195236, GNT1194667, GNT2008382), and AP by NHMRC Senior Research Fellowship (1154389). AS is supported by NEI Intramural Research Program (Z01EY000546). This work was also made possible through the Victorian State Government Operational Infrastructure Support and the NHMRC Independent Research Institute Infrastructure Support Scheme (IRIISS). The Alienor cohort was funded by Laboratoires Thea (Clermont_Ferrand, France), Universite de Bordeaux (Bordeaux, France), Fondation Voir et Entendre (Paris, France), Agence Nationale de la Recherche (2010_PRSP_011), CFSR Recherche (Club Francophone des Specialistes de la Retine), the French Ministry of Health (PHRC, 2012, PHRC12_157 ECLAIR) and CNSA (Caisse Nationale pour la Solidarite et l Autonomie) (Paris, France). The Alienor study is based on the Three_City Study, which is conducted under a partnership agreement between the Institut National de la Sante et de la Recherche Medicale (INSERM), the Institut de Sante Publique, Epidemiologie et Developpement of the University of Bordeaux and Sanofi_Aventis. The Fondation pour la Recherche Medicale funded the preparation and initiation of the study. The Three_City Study is also supported by the Caisse Nationale Maladie des Travailleurs Salaries, Direction Generale de la Sante, Mutuelle Generale de l Education Nationale, Institut de la Longevite, Regional Governments of Aquitaine and Bourgogne, Fondation de France, Ministry of Research_INSERM Programme Cohortes et collections de donnees biologiques, French National Research Agency COGINUT ANR_06_PNRA_005 and ANR 2007LVIE 003, the Fondation Plan Alzheimer (FCS 2009_2012), the Caisse Nationale pour la Solidarite et l Autonomie (CNSA), and Roche Pharma. AM is supported by the French National Research Agency (ANR) grants ANR_23_CE12_0029_01, ANR_22_NEU2_0004_02 and Fondation Vaincre Alzheimer generic grant. Computations were performed on the Bordeaux Bioinformatics Center (CBiB) and the CREDIM computer resources, University of Bordeaux (funding provided to Pr. Stephanie Debette by the Fondation Claude Pompidou). The AREDS2_OCT and NEI_research studies were supported by the intramural program funds and contracts from the National Eye Institute/National Institutes of Health (NEI/NIH), Department of Health and Human Services, Bethesda, MD. Contract No. HHS_N_260_2005_00007_C. ADB Contract No. N01_EY_5_0007. Funds were generously contributed to these contracts by the following NIH institutes: Office of Dietary Supplements (ODS), National Center for Complementary and Alternative Medicine (NCCAM) now known as National Center for Complementary and Integrative Health (NCCIH), National Institute on Aging (NIA), National Heart, Lung and Blood Institute (NHLBI), and National Institute of Neurological Disorders and Stroke (NINDS). The DUKE FEATURE study was supported by the National Eye Institute, National Institutes of Health, Bethesda, Maryland (grant no.: K23EY026988 [to E.M.L.]); F. Hoffmann La Roche Ltd., Basel, Switzerland (E.M.L. through Duke University). The Genentech/Roche GWAS cohort (CHROMA and SPECTRI studies) and whole genome sequencing cohort were funded by F.Hoffman_LaRoche Ltd. The Hadassah study was supported by an Israel Science Foundation grant (#3485/19). The MACUSTAR project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116076. This Joint Undertaking has received support from the European Unions Horizon 2020 research and innovation program and EFPIA. This communication reflects the authors view and neither IMI nor the European Union nor EFPIA are responsible for any use that may be made of the information contained therein. The NICOLA study received grant support from Bayer and Novartis for retinal grading.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In this study, prior to data collection, comprehensive ethical approvals were obtained from all relevant institutional review boards or ethics committees (Supplementary Table S15). The study was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the tenets of the Declaration of Helsinki, and all enrolled participants provided written informed consent. Each ethical agreement was approved by the Walter and Eliza Hall Institute of Medical Research Human Research Ethics Committee (HREC, project number 20/13LR) where the final analysis was performed.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors